Video

Pharmacist Medication Insights: for Panzyga for Primary Humoral Immunodeficiency

Author(s):

Saro Arakelians, PharmD

Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.

Panzyga (immune globulin intravenous [Human]-ifas) is indicated for the following:

  • For the treatment of adults 18 years of age and older with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
  • Primary humoral immunodeficiency (PI) in patients 2 years of age and older.
  • Chronic immune thrombocytopenia (ITP) in adults.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image credit: Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: kitsawet | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Related Content
Breast cancer cells | Image Credit: © sknab - stock.adobe.com
July 11th 2025

Dalpiciclib Plus Endocrine Therapy Prolonged Invasive Disease-Free Survival in HR+/HER2– Breast Cancer

Alexandra Gerlach, Associate Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Close-up of leukemia cells | Image Credit: © Brighting Collection - stock.adobe.com
July 9th 2025

Zanubrutinib Linked to Lower Infection Risk Than Venetoclax Plus Obinutuzumab in Real-World CLL/SLL Study

Alexandra Gerlach, Associate Editor
Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care
June 17th 2025

Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Visualization of plasma cell in multiple myeloma | Image Credit: © ArtificialHorizons - stock.adobe.com
July 8th 2025

Isa-KRD Induction Achieves 95% Response Rate in Multiple Myeloma

Alexandra Gerlach, Associate Editor
Microscopic view of breast cancer cells | Image Credit: © Jack - stock.adobe.com
July 8th 2025

Radiation or Immune-Modulating Drugs Could Mitigate Resistance to CDK4/6 Inhibitors in Breast Cancer

Alexandra Gerlach, Associate Editor